CoChat

Treatment with Synthetic Glucocorticoids and the Hypothalamus-Pituitary-Adrenal Axis

Open access
Paragliola, Rosa Maria, Papi, Giampaolo, Pontecorvi, Alfredo, Corsello, Salvatore Maria · 2017 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index; 24 of the 199 sources its claims cite were checked for support.

Abstract

Chronic glucocorticoid (GC) treatment represents a widely-prescribed therapy for several diseases in consideration of both anti-inflammatory and immunosuppressive activity but, if used at high doses for prolonged periods, it can determine the systemic effects characteristic of Cushing’s syndrome. In addition to signs and symptoms of hypercortisolism, patients on chronic GC therapy are at risk to develop tertiary adrenal insufficiency after the reduction or the withdrawal of corticosteroids or during acute stress. This effect is mediated by the negative feedback loop on the hypothalamus-pituitary-adrenal (HPA) axis, which mainly involves corticotropin-release hormone (CRH), which represents the most important driver of adrenocorticotropic hormone (ACTH) release. In fact, after withdrawal of chronic GC treatment, reactivation of CRH secretion is a necessary prerequisite for the recovery of the HPA axis. In addition to the well-known factors which regulate the degree of inhibition of the HPA during synthetic GC therapy (type of compound, method of administration, cumulative dose, duration of the treatment, concomitant drugs which can increase the bioavailability of GCs), there is a considerable variation in individual physiology, probably related to different genetic profiles which regulate GC receptor activity. This may represent an interesting basis for possible future research fields.

Overview

CoChat Summary

TL;DR

Chronic synthetic glucocorticoid therapy can suppress the hypothalamus-pituitary-adrenal (HPA) axis and cause tertiary adrenal insufficiency, especially after dose reduction or withdrawal. Risk is shaped by compound, route, dose, duration, drug interactions, and individual genetic variation, while incidence estimates remain uncertain because diagnostic criteria vary.

Key findings

  • Chronic glucocorticoids inhibit CRH and ACTH; after withdrawal, reactivation of CRH secretion is a necessary prerequisite for HPA axis recovery. A cited systematic review found hypoadrenalism persisted in 15% of patients retested three years after glucocorticoid withdrawal.
  • Exposure is common: in 2008 almost 1% of the UK adult population were exposed to oral glucocorticoids, including 0.79% on long-term courses longer than three months. About 6% of hospitalized patients may have glucocorticoid-induced adrenal insufficiency, and prevalence estimates from large observational studies range from 14–63%.
  • Adrenal crisis incidence was reported as 15.1/100 patient-years in tertiary adrenal insufficiency, compared with 5.2/100 patient-years in primary and 3.6/100 patient-years in secondary adrenal insufficiency. Infections were the most important precipitant, and about 30% of tertiary adrenal insufficiency crises occurred after glucocorticoid dose reduction.
  • Risk predictors include prednisone >20 mg/day for >3 weeks making HPA suppression “likely,” evening/bedtime prednisone ≥5 mg for more than a few weeks also increasing risk, and 10–20 mg/day for >3 weeks being intermediate risk. Hydrocortisone and cortisone acetate are least suppressive; dexamethasone is the most potent ACTH suppressor.

Methods

  • Narrative review evaluating the physiopathology and clinical effects of synthetic glucocorticoids on HPA function.
  • Synthesizes literature on normal HPA physiology, synthetic glucocorticoid pharmacology, receptor biology, clinical adrenal insufficiency, and genetic variability, including cited systematic reviews, observational studies, animal models, and in vitro assays.
  • No primary data collection or systematic search strategy is reported.

Limitations

  • The paper states that a clear incidence of glucocorticoid-induced adrenal insufficiency cannot be assessed because of substantial differences in diagnostic criteria and variability in tests, including standard- and low-dose ACTH tests, insulin tolerance tests, and CRH stimulation, with different cut-offs and sensitivity/specificity.
  • The paper notes that in vitro receptor transactivation systems differ from in vivo conditions, including steroid-metabolizing enzymes and heat shock protein concentrations, and that the literature on rapid glucocorticoid feedback is confusing and limited by not considering endogenous cortisol pulses.
  • Evident from the text: as a narrative review, it does not describe a systematic search or formal quality appraisal, and many clinical estimates rely on heterogeneous cited studies.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/ijms18102201

Cites

93 of 93 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Daily cortisol rhythm in healthy volunteers [23].
Figure 1 Daily cortisol rhythm in healthy volunteers [23].CC BY · PubMed Central
Figure 2 Corticotropin-release hormone (CRH) knock-out (KO) mouse model in regulation of hypothalamus-pituitary-adrenal (HPA) axis [59]. In CRH KO models proopiomelanocortin (POMC) mRNA, but not plasmatic adrenocorticotropic hormone (ACTH), rises after adrenalectomy. Glucocorticoids, but not mineralocorticoids (blue dotted arrow) reduce POMC increase induced by adrenalectomy. CRH administration restores a significant ACTH secretion.
Figure 2 Corticotropin-release hormone (CRH) knock-out (KO) mouse model in regulation of hypothalamus-pituitary-adrenal (HPA) axis [59]. In CRH KO models proopiomelanocortin (POMC) mRNA, but not plasmatic adrenocorticotropic hormone (ACTH), rises after adrenalectomy. Glucocorticoids, but not mineralocorticoids (blue dotted arrow) reduce POMC increase induced by adrenalectomy. CRH administration restores a significant ACTH secretion.CC BY · PubMed Central
Figure 3 Tissue side effects of synthetic glucocorticoids [1].
Figure 3 Tissue side effects of synthetic glucocorticoids [1].CC BY · PubMed Central

Verification

Claims the paper makes

24 Valid · 2 Not valid · 161 Not checked · 24 Own results and interpretations

146 more claims · 15 with their cited sources checked

Create a free account to see all 211 claims and to verify the 175 references still open.

See all claims — free account
  • Probably not a substantial claim. 13
  • It may state two separate claims as one. 52
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Cited by

See all 181

Metadata

Authors
Paragliola, R. M., Papi, G., Pontecorvi, A., & Corsello, S. M.
Affiliations
Università Cattolica del Sacro Cuore (IT)
Corresponding author
Corsello, Salvatore Maria
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2017-10-20
Volume
18
Issue
10
Pages
2201
ISSN
1422-0067 (ISSN-L)
OpenAlex
W2765223108
Cited by
181
References
93
Citations by year
2026: 10 · 2025: 16 · 2024: 23 · 2023: 23 · 2022: 25 · 2021: 34 · 2020: 16 · 2019: 23 · 2018: 10 · 2017: 1
FWCI
1.99
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
Keywords
synthetic glucocorticoids, hypothalamic-pituitary-adrenal axis, Cushing's syndrome, tertiary adrenal insufficiency, corticotropin-releasing factor, ACTH, glucocorticoid withdrawal
MeSH terms
Adrenocorticotropic Hormone, Animals, Corticotropin-Releasing Hormone, Cushing Syndrome, Glucocorticoids, Humans, Hypothalamo-Hypophyseal System, Pituitary-Adrenal System, Feedback, Physiological

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.